Accordingly, tumors responding to denosumab presented at baseline higher scores for these RL-driven genes in mouse MECs and PyMT tumor cells (Fig. 5g and Supplementary Fig. 6e), and RANK and NF-κB pathway gene signatures (Supplementary Fig. 6f). Here, TNFRSF11A is linked to neoplasm.